Stockreport

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF COBENFY is the first major advance in schizophrenia treatment in decades, offering a novel mechanism of action distinct from other therapiesCOBENFY has already been incl [Read more]